Compare Gilead Sciences, Inc. (GILD) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares Ultra QQQ ETF — how do they compare? Gilead Sciences, Inc. trades at $133.42 (market cap $163.51B), while ProShares Ultra QQQ ETF trades at $89.85. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | QLD | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $100.53 |
52-Week Low | $108.22 | $57.16 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QLD, the ProShares Ultra QQQ ETF, is a 2x daily leveraged fund tracking the Nasdaq-100. The stock trades at $90.15, down 2.14% on the day, with a technical signal leaning bearish. Key financial ratios are not applicable for this ETF structure, which amplifies daily index returns. Recent news highlights its long-term performance and role in tactical portfolios, while technical analysis shows immediate support near $90.
The outlook hinges on the direction of the tech-heavy Nasdaq-100. The fund offers amplified exposure for tactical bullish bets but carries significant volatility and decay risks in sideways or declining markets. Its bearish technical signals and leveraged nature make it suitable only for investors with high risk tolerance and a short-term horizon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
